DENTSPLY SIRONA Inc. (XRAY) 股票分析
医疗保健DENTSPLY SIRONA Inc.
$9.99
$-0.22 (-2.15%)
最后更新: 2026年5月26日
价格走势
暂无价格数据
最新新闻
Dentsply Sirona to Participate in the 2026 Stifel Jaws & Paws Conference
Yahoo·Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know
Yahoo·
新闻由第三方来源提供。不构成投资建议。
分析
公司概述
DENTSPLY SIRONA Inc. operates as a global provider of dental equipment supported by cloud-enabled solutions, alongside dental products and healthcare consumables utilized in urology and enterology. The company functions within the Healthcare sector, specifically the Medical Instruments & Supplies industry, positioning it as a critical supplier to the specialized medical device market. Its operational scale is defined by a market capitalization of $2.39B and an annual revenue of $3.68B, supported by a workforce of 14,000 employees. These financial dimensions indicate that while the company maintains a substantial physical presence and revenue stream, its market valuation relative to earnings suggests a complex capital structure typical of capital-intensive manufacturing firms facing margin compression.
财务健康
The company reported a trailing twelve-month revenue of $3.68B, yet simultaneously recorded a net income loss of $598,000,000 and an EBITDA of $597.00M, a divergence that reveals a significant structural cost burden or non-operating expenses eroding bottom-line profitability despite positive cash generation from core operations. This gap between revenue and net income highlights the heavy overhead costs or interest expenses impacting the profit margin, which stands at -16.2%, contrasting sharply with the robust 50.0% gross margin and the slender 1.8% operating margin. While the gross margin reflects strong pricing power or high-value product mix, the operating margin indicates that overheads are consuming nearly all operating profits, and the negative profit margin confirms that the current period's losses are driven by factors extending beyond just operational inefficiencies. The firm generated $106.38M in free cash flow, which provides a degree of financial flexibility to service debt or fund operations despite the accounting losses. On the balance sheet, the company holds $354.00M in cash against $2.48B in total debt, resulting in a debt-to-equity ratio of 185.00, which characterizes a highly leveraged financial structure where debt obligations significantly exceed equity capitalization. Liquidity management is supported by a current ratio of 1.51, indicating that current assets are sufficient to cover short-term liabilities with a comfortable buffer. Return metrics further illustrate the impact of this leverage and loss position, with a return on equity of -36.4% signaling poor returns on shareholder capital, while a return on assets of 2.7% suggests that assets are generating minimal positive returns on a pre-interest basis.
估值评估
Valuation multiples for DENTSPLY SIRONA Inc. present a mixed picture, with a trailing P/E ratio marked as N/A due to the current net income losses, while the forward P/E is 7.71, implying that the market expects a significant earnings turnaround in the coming fiscal periods. The price-to-book ratio stands at 1.79, suggesting that the market values the company at a 79% premium over its tangible book value, which may reflect intangible assets or future growth expectations despite current earnings struggles. Alternative valuation metrics provide additional context, with a price-to-sales ratio of 0.65 and an EV/EBITDA of 7.57, indicating that the stock is priced at a discount relative to sales but commands a reasonable multiple based on cash earnings before interest, taxes, depreciation, and amortization. The stock has traded within a 52-week range between a low of $9.85 and a high of $17.18, and based on the available data, the valuation assessment must rely on these historical bounds to gauge relative position, though specific current price placement requires the latest trading data not explicitly provided beyond these limits. The beta of 1.00 indicates that the stock's price volatility mirrors the broader market movements, offering no inherent defensive or aggressive characteristic relative to the S&P 500.
Growth & Income
Growth dynamics are mixed, with revenue growth year-over-year at 6.2% while earnings growth is N/A, reflecting the reality that top-line expansion is not currently translating into bottom-line improvement. The divergence between growing revenue and stagnant or negative earnings suggests that cost pressures or one-time charges are outpacing revenue gains, necessitating a strategic focus on margin expansion to drive future profitability. Regarding income generation, the company offers a dividend yield of 5.0% with a payout ratio of 28.8%, which appears sustainable given that the payout is derived from free cash flow rather than accounting net income, though the negative net income complicates the traditional sustainability analysis. The overall growth and income profile presents a scenario where investors receive current income via dividends while the company focuses on stabilizing earnings through operational improvements, as indicated by the strong revenue growth and positive free cash flow generation.
同行比较
DENTSPLY SIRONA Inc. (XRAY) 在医疗器械与用品行业运营。以下是其与市值最接近的同行的比较:
| 公司 | 代码 | 市值 | 市盈率 |
|---|---|---|---|
| DENTSPLY SIRONA Inc. | XRAY | $2.00B | N/A |
| Intuitive Surgical, Inc. | ISRG | $154.64B | 53.2 |
| Becton, Dickinson and Company | BDX | $40.71B | 25.8 |
| Alcon Inc. | ALC | $33.02B | 40.5 |
医疗器械与用品行业平均市盈率为208.0倍。DENTSPLY SIRONA Inc.的市盈率为N/A。
本分析由AI生成,仅供参考,不构成投资建议。数据可能存在延迟或不准确。在做出投资决策之前,请务必进行自己的研究并咨询合格的财务顾问。
相关医疗器械与用品股票
Intuitive Surgical, Inc.
$154.64B
BDXBecton, Dickinson and Company
$40.71B
ALCAlcon Inc.
$33.02B
MDLNMedline Inc.
$30.58B
RMDResMed Inc.
$30.18B
WSTWest Pharmaceutical Services, Inc.
$22.34B
医疗保健热门股票
Eli Lilly and Company
$949.47B
JNJJohnson & Johnson
$554.09B
ABBVAbbVie Inc.
$376.54B
UNHUnitedHealth Group Incorporated
$342.24B
MRKMerck & Co., Inc.
$302.33B
关于DENTSPLY SIRONA Inc.
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as well as CEREC, a full-chairside economical restoration of esthetic ceramic dentistry offering. The Essential Dental Solutions segment provides motorized endodontic handpieces, files, sealers, irrigation needles, and other tools for root canal procedures; restorative products; curing light and dental diagnostic systems; ultrasonic scalers and polishers; and dental anesthetics, prophylaxis paste, dental sealants, and impression materials. The Orthodontic and Implant Solutions segment offers SureSmile, a clear aligner solution that includes whitening kits and retainers; VPro, a high frequency vibration technology device; SureSmile Simulator; DS Core platform, which creates 3D visualization of patient outcomes; dental implant products; digital dentures; crown and bridge porcelain products; bone regenerative and restorative solutions; treatment planning software; educational programs; custom abutments; tapered immediate load screws; regenerative bone growth factor; artificial teeth; and precious metal dental alloys. The Wellspect Healthcare segment offers medical devices, including catheters for urinary retention and advanced irrigation systems to help people suffering from chronic or severe constipation. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina.
公司简介以英文显示。
访问官网 →